LOUISVILLE, Kentucky—Humana Inc. announced that it has signed a definitive agreement with a consortium of investors to divest its minority interest in hospice and palliative care provider Gentiva—the last step in the insurer's exit from the end-of-life care business.
The deal values Humana’s minority interest stake at approximately $900 million. Other financial terms were not disclosed. Humana said it intends to use proceeds from the sale for general corporate purposes. The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and other customary closing conditions, and the company said it does not anticipate a material impact to 2026 earnings from this pending transaction.
Humana’s had a 40% minority ownership stake in Gentiva remaining from its 2021 acquisition of Kindred at Home (KAH). At that time, Humana indicated it indended to ultimately divest non-core KAH businesses, including hospice, palliative and personal health care services.
In 2022, Humana announced an agreement to divest a majority interest in the hospice and personal care divisions of Humana’s Kindred at Home subsidiary (KAH Hospice) to private investment firm Clayton, Dubilier & Rice (CD&R). These divisions were then subsequently restructured into a standalone business and rebranded to Gentiva.